Atlas companies are custom built to realize their scientific and business potential.
Discover: Identifying true innovation from high-impact science.
Derisk: Proving and maturing the science and technology to guide clinical translation.
Shape: Crafting the right business model for each opportunity.
Strengthen: Rolling up our sleeves to position our companies for successful drug development and exits in all market environments.
The opportunity determines the model—not the other way around. Our portfolio includes a diverse set of investment approaches:
Drug Discovery Platforms: Launching “big science” companies on the path to clinical and commercial success with multiple opportunities for liquidity. Examples include Avila, CoStim, Nimbus Therapeutics, miRagen, Padlock Therapeutics, and Raze. Learn more
Asset-Centric: Bringing promising therapeutics to clinical proof-of-concept. Examples include Zafgen and Stromedix. Learn more
Built-to-Buy: Partnering with large pharma and biotech companies to advance individual assets. Structured acquisition agreements with our partners can drive rapid exits and strong returns. Examples include Spero Therapeutics, Arteaus Therapeutics, and Annovation. Learn more